SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Is WntResearch close to a deal with BP ?
WNT.ST 5.300-2.2%Feb 24 3:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
From: loparn8/31/2017 1:58:58 PM
   of 4
 
Surprisingly the CEO of WntResearch resigned last Friday. My best guess is that he could not deliver a good enough deal with Big Pharma according to the board and CSO who know the value of Foxy-5. aktietorget.se

But strange things have happened the last few days. Research raw data (before publication !) for WntResearch's Foxy-5 is available now on this site :

Treatment with the WNT5A-mimicking Peptide Foxy-5 Effectively Reduces the Metastatic Spread of WNT5A-low Prostate Cancer Cells in an Orthotopic Mouse Model

figshare.com

figshare.com

The short and just 2 days old article above regarding the 3D-structure of Foxy-5 and Wnt-5a is written by a long time stockholder (had 99 000 shares as of June 30 2017) and scientist. It supports my own conclusion that Foxy-5 mechanistically via Frizzled-5 most likely captures only the best antimetastatic signaling pathway of Wnt-5a and not the unwanted signaling via the receptors Frizzled-2, Frizzled-7 and ROR2 in breast, colon and prostate cancers.

WntResearch has cancelled their presentation at Nordic Life Science Days Sept 14, and will only participate. So I intepret this that an adequate number of Big Pharma now probably are already serious partner candidates eager to get Foxy-5 :-)

No presentations to the stock market are planned, in spite of the weak balance sheet.

Many clues now point to that a deal regarding Foxy-5 may occur rather soon (I hope) , and could finance Phase II clinical studies with Foxy-5 in breast, colorectal and prostate cancers !

The WNT.ST stock is very volatile now, but once more seem to pull upwards in new optimism :
finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext